×

Cellular Biomedicine Group Completes Twelve-Month Follow-Up of Patients From Phase I/IIa Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis

PALO ALTO, Calif., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the completion of the twelve-month follow-up of patients from the Phase I/IIa trial, which evaluates the safety and efficacy of the Company's proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoinTM for Knee Osteoarthritis (KOA).

With treatment completed in 2013, all patients in the Phase I/IIa trial have now undergone twelve-month follow-up tests, which include WOMAC, NRS-11, SF-36 and KSCRS indices as well as knee articular cartilage volume assessment through quantitative magnetic resonance imaging (MRI) evaluation. The six-month follow-up data analysis previously concluded that ReJoinTM cell therapy for KOA patients is safe and revealed an increase in cartilage volume as early as three months after the therapy. (click here to view detailed six-month data).

Dr. William (Wei) Cao, Chief Executive Officer of the Company, commented, "We are very pleased with the smooth progress of our trials for KOA. The excellent readout from the six-month follow-up of the Phase I/IIa trial makes us optimistic about the data from this twelve-month follow-up. We expect the official report to be available in the fourth quarter of 2014."

The Phase I/IIa trial was conducted by Shanghai's Renji Hospital, a tertiary hospital affiliated to Shanghai Jiao Tong University School of Medicine. The twelve-month data analysis has been completed by statisticians of the Biostatistics Research and Teaching Section, Public Health College, Shanghai Fudan University and will be reviewed by the Principal Investigator ChunDe Bao, MD, Professor of Medicine, Vice Chairman of the Chinese Rheumatology Association.

Cellular Biomedicine Group is currently running a multi-center Phase IIb clinical trial for ReJoinTM, which further studies the efficacy of CBMG's proprietary haMPC-based therapy for KOA.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 646 284-9427 Vivian.chen@grayling.com

Source:Cellular Biomedicine Group Inc.